JP2022547809A5 - - Google Patents
Info
- Publication number
- JP2022547809A5 JP2022547809A5 JP2022510984A JP2022510984A JP2022547809A5 JP 2022547809 A5 JP2022547809 A5 JP 2022547809A5 JP 2022510984 A JP2022510984 A JP 2022510984A JP 2022510984 A JP2022510984 A JP 2022510984A JP 2022547809 A5 JP2022547809 A5 JP 2022547809A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- cell
- acid sequence
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962889519P | 2019-08-20 | 2019-08-20 | |
| US62/889,519 | 2019-08-20 | ||
| PCT/US2020/047071 WO2021034976A1 (en) | 2019-08-20 | 2020-08-19 | T-cell immunotherapy specific for wt-1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547809A JP2022547809A (ja) | 2022-11-16 |
| JP2022547809A5 true JP2022547809A5 (cg-RX-API-DMAC10.html) | 2023-08-29 |
| JP7737978B2 JP7737978B2 (ja) | 2025-09-11 |
Family
ID=72473955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022510984A Active JP7737978B2 (ja) | 2019-08-20 | 2020-08-19 | Ｗｔ－１に特異的なｔ細胞免疫療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12653886B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4017872A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7737978B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220050176A (cg-RX-API-DMAC10.html) |
| CN (1) | CN114555790B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020334064A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3147717A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL290609A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021034976A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202406990D0 (en) * | 2024-05-16 | 2024-07-03 | Univ Oxford Innovation Ltd | T cell receptors and uses thereof |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
| WO2026125718A1 (en) * | 2024-12-13 | 2026-06-18 | Immunoscape Pte. Ltd. | Human t cell receptors and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| AU4932199A (en) | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
| US8206965B2 (en) | 2002-03-15 | 2012-06-26 | Cellectis S.A. | Hybrid and single chain meganucleases and use thereof |
| EP1550453B1 (en) | 2002-09-12 | 2015-05-27 | International Institute of Cancer Immunology, Inc. | Cancer antigen peptide preparation |
| US20060206949A1 (en) | 2003-01-28 | 2006-09-14 | Sylvain Arnould | Custom-made meganuclease and use thereof |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| PT1731605E (pt) | 2004-03-31 | 2010-04-14 | Int Inst Cancer Immunology Inc | Péptidos antigénicos de cancro derivados de wt1 |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| AU2013361275B2 (en) | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
| EP3760719A1 (en) | 2013-11-18 | 2021-01-06 | CRISPR Therapeutics AG | Crispr-cas system materials and methods |
| JP6476182B2 (ja) * | 2013-11-22 | 2019-02-27 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 改変された高親和性ヒトｔ細胞受容体 |
| US11390921B2 (en) * | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
| EP3177314B1 (en) * | 2014-08-04 | 2020-10-07 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
| TW201625689A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗－ｂ７－ｈ４抗體及免疫結合物 |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| IL254039B2 (en) | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| US11047011B2 (en) | 2015-09-29 | 2021-06-29 | iRepertoire, Inc. | Immunorepertoire normality assessment method and its use |
| WO2017112944A1 (en) | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| AU2017232431A1 (en) | 2016-03-15 | 2018-09-20 | Cancer Research Technology Limited | Chimeric antigen receptor |
| KR102397771B1 (ko) | 2016-09-23 | 2022-05-13 | 프레드 헛친슨 켄서 리서치 센터 | 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도 |
| EA201992536A1 (ru) | 2017-04-24 | 2020-03-05 | Оспедале Сан Раффаэле С.Р.Л. | Tcr и пептиды |
| PL3765615T3 (pl) | 2018-03-14 | 2023-11-13 | Arbor Biotechnologies, Inc. | Nowe enzymy i układy crispr ukierunkowane na dna |
-
2020
- 2020-08-19 KR KR1020227009102A patent/KR20220050176A/ko not_active Ceased
- 2020-08-19 EP EP20771665.5A patent/EP4017872A1/en not_active Withdrawn
- 2020-08-19 WO PCT/US2020/047071 patent/WO2021034976A1/en not_active Ceased
- 2020-08-19 US US17/636,314 patent/US12653886B2/en active Active
- 2020-08-19 JP JP2022510984A patent/JP7737978B2/ja active Active
- 2020-08-19 AU AU2020334064A patent/AU2020334064A1/en not_active Abandoned
- 2020-08-19 CA CA3147717A patent/CA3147717A1/en active Pending
- 2020-08-19 CN CN202080071763.9A patent/CN114555790B/zh active Active
-
2022
- 2022-02-14 IL IL290609A patent/IL290609A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11932700B2 (en) | Use of chimeric antigen receptor modified cells to treat cancer | |
| JP2024074801A5 (cg-RX-API-DMAC10.html) | ||
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| Fan et al. | Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia | |
| Feldman et al. | Adoptive cell therapy—tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors | |
| JP2017523784A5 (cg-RX-API-DMAC10.html) | ||
| US20230265207A1 (en) | T cell-antigen coupler with y182t mutation and methods of uses thereof | |
| US10654934B2 (en) | Use of chimeric antigen receptor modified cells to treat cancer | |
| JP2020509767A5 (cg-RX-API-DMAC10.html) | ||
| JP2017531687A5 (cg-RX-API-DMAC10.html) | ||
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| JP2021512637A5 (cg-RX-API-DMAC10.html) | ||
| JP2022525099A5 (cg-RX-API-DMAC10.html) | ||
| JP2022527267A5 (cg-RX-API-DMAC10.html) | ||
| BR112021000735A2 (pt) | acoplador de antígeno de células t com várias otimizações de construto | |
| JP2022523971A5 (cg-RX-API-DMAC10.html) | ||
| Pircher et al. | T cell engineering | |
| JP2022523553A5 (cg-RX-API-DMAC10.html) | ||
| JP2022543059A5 (cg-RX-API-DMAC10.html) | ||
| JP2021525067A5 (cg-RX-API-DMAC10.html) | ||
| WO2018064921A1 (en) | Use of chimeric antigen receptor modified cells to treat cancer | |
| JP2022543058A5 (cg-RX-API-DMAC10.html) | ||
| JP2022543060A5 (cg-RX-API-DMAC10.html) | ||
| Hanagiri et al. | Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes | |
| Smith et al. | Immunotherapy of colorectal cancer |